US2014193473A1PendingUtilityA1
Materials and methods for controlling vasculogenesis from endothelial colony forming cells
Individually held — no corporate assignee on recordPriority: Jun 2, 2011Filed: Jun 6, 2012Published: Jul 10, 2014
Est. expiryJun 2, 2031(~4.9 yrs left)· nominal 20-yr term from priority
A61L 27/24A61L 27/3808A61K 35/51A61K 9/70
47
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Materials and methods are disclosed for controlling vasculogenesis using building blocks of a collagen matrix and endothelial colony forming cells (ECFC). The building blocks may be isolated by fractionating an acid soluble Type I collagen. The building blocks comprising monomers and/or oligomers may be recombined in desired ratios to alter the matrix microenvironment and to influence ECFC behavior.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A vessel forming matrix comprising:
a population of endothelial colony forming cells in a polymerized matrix comprising at least one fraction of an acid soluble Type I collagen.
2 . The matrix according to claim 1 , wherein said at least one fraction of the acid soluble Type I collagen is selected from the group consisting of monomers having an average molecular weight of about 282 kDa and oligomers having an average molecular weight of about 603 kDa.
3 . The matrix according to claim 1 , wherein said at least one fraction of acid soluble Type I collagen includes a telopeptide reactive aldehyde.
4 . The matrix according to claim 1 , further comprising a second fraction of the acid soluble Type I collagen that differs from the at least one fraction.
5 . The matrix according to claim 4 , wherein the at least one fraction is an oligomer-rich fraction and the second fraction is a monomer-rich fraction.
6 . The matrix according to claim 5 , wherein the matrix comprises more of the oligomer-rich fraction than the monomer-rich fraction.
7 . The matrix according to claim 1 , wherein said at least one fraction of acid soluble Type I collagen is present in the matrix at a concentration of about 0.5 to about 3.0 mg/ml.
8 . The matrix according to claim 1 , wherein said population of endothelial colony forming cells is present in the matrix at a concentration of about 5×10 5 to about 2×10 6 cells/ml.
9 . A method of promoting vessel formation comprising the steps of:
obtaining an engineered collagen matrix from an oligomer-rich fraction of a Type I acid soluble collagen; and seeding the matrix with a plurality of endothelial colony forming cells to form one or more vessels within the matrix.
10 . The method according to claim 9 , wherein the matrix is richer in Type I acid soluble collagen oligomers than in Type I acid soluble collagen monomers.
11 . The method according to claim 9 , wherein the average molecular weight of the collagen in the matrix is about 603 kDa.
12 . The method according to claim 9 , wherein the average molecular weight of the collagen in the matrix is greater than about 282 kDa.
13 . The method according to claim 9 , wherein the matrix has a collagen concentration of about 0.5 to about 3.0 mg/ml.
14 . The method according to claim 9 , wherein the obtaining step comprises isolating oligomers from the Type I acid soluble collagen.
15 . The method according to claim 9 , wherein the matrix is stiffer than the Type I collagen.
16 . The method according to claim 9 , wherein the matrix is in an unpolymerized state during the seeding step.
17 . The method according to claim 9 , wherein the seeding step comprises seeding the matrix with about 5×10 5 to about 2×10 6 cells/ml.
18 . The method according to claim 9 , further comprising the step of implanting the matrix into a diseased area of a patient.
19 . The method according to claim 18 , wherein the diseased area of the patient comprises an ischemic limb.
20 . The method according to claim 9 , wherein the obtaining step comprises independently controlling a stiffness of the matrix and a collagen concentration of the matrix.Join the waitlist — get patent alerts
Track US2014193473A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.